Hyperthermic Intraperitoneal Chemotherapy

A cancer treatment that involves filling the abdominal cavity with heated chemotherapy drugs. It is performed after the surgeon removes tumors or lesions from the abdominal area, to kill any cancer cells that remain after surgery and reduce the risk for cancer recurrence. (From: https://www.mdanderson.org/treatment-options/hyperthermic-intraperitoneal-chemotherapy.html; Feb, 20, 2020).

Also Known As:

Networked: 2959 relevant articles (397 outcomes, 587 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Levine, Edward A: 89 articles (06/2022 - 01/2003)
2.	Glehen, Olivier: 82 articles (04/2022 - 07/2005)
3.	Shen, Perry: 69 articles (06/2022 - 01/2003)
4.	Deraco, Marcello: 66 articles (08/2022 - 11/2006)
5.	Sugarbaker, Paul H: 59 articles (04/2022 - 12/2009)
6.	Baratti, Dario: 56 articles (08/2022 - 11/2006)
7.	Kusamura, Shigeki: 56 articles (03/2022 - 11/2006)
8.	Morris, David L: 50 articles (06/2022 - 11/2008)
9.	Piso, Pompiliu: 44 articles (11/2022 - 06/2004)
10.	Votanopoulos, Konstantinos I: 42 articles (06/2022 - 09/2012)

Related Diseases

1.	Peritoneal Neoplasms 05/01/2015 - "Prospective randomized trials are warranted to determine which drug is the most effective for HIPEC in each type of peritoneal surface malignancy. " 12/01/2014 - "CRS combined with HIPEC is becoming the gold standard treatment for resectable peritoneal carcinomatosis in highly selected patients. " 08/01/2012 - "Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the best treatment of several peritoneal surface malignancies. " 03/17/2020 - "The role of hyperthermic intraperitoneal chemotherapy (HIPEC) has been acknowledged as prophylaxis for peritoneal carcinomatosis (PC) in AGC patients and in this study, we aim at investigating the safety and efficacy of the combination of neoadjuvant laparoscopic HIPEC (NLHIPEC) with NAC in the neoadjuvant phase followed by surgery of curative intent with intraoperative HIPEC followed by adjuvant chemotherapy (AC). " 06/08/2023 - "Prognostic factors for longer OS include a more complete cytoreduction (pooled OR = 5.35; p < 0.00001), which correlated with a peritoneal carcinomatosis index below 7. Novel treatment strategies, such as HIPEC and PIPAC, are promising in the management of GC/PC. "
2.	Neoplasm Metastasis (Metastasis) 11/01/2022 - "Survival of patients affected by colorectal cancer peritoneal metastases (CRC-PM) can be improved with combined complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). " 11/01/2014 - "Complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is on the verge of becoming the gold standard treatment for selected patients presenting peritoneal metastases (PM) of colorectal origin. " 08/28/2023 - "Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still beneficial in patients diagnosed with colorectal peritoneal metastasis who underwent palliative chemotherapy?" 10/01/2022 - "Systemic chemotherapy is associated with improved OS for high-grade MAC patients with unresectable peritoneal metastases who are deemed surgical candidates but underwent an unsuccessful CRS/HIPEC attempt. " 12/23/2021 - "These strategies, including radical surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) showed surprisingly good results, leading to the prolonged survival of patients with peritoneal metastasis. "
3.	Neoplasms (Cancer) 09/07/2014 - "The advent of cytoreduction (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. " 11/01/2021 - "Peritoneal Cancer Index (PCI) and complete cytoreduction are the best outcome predictors following cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). " 01/01/2018 - "The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies. " 01/01/2016 - "Intraperitoneal free cancer cells (IFCCs) play a very important role in forming PC, but the administration of intraperitoneal chemotherapy (IPC) and/or hyperthermic intraperitoneal chemotherapy (HIPEC) could be an effective treatment for IFCCs. " 11/21/2013 - "Only few patients may also benefit from hyperthermic intraperitoneal chemotherapy with a complete tumor remission. "
4.	Ovarian Neoplasms (Ovarian Cancer) 07/01/2014 - "We analyze the efficacy of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) for microscopic residual disease in patients with stage IIIC/IV ovarian cancer after a complete cytoreduction of their disease. " 12/16/2021 - "Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial." 09/01/2020 - "In a meta-analysis including two randomized, controlled studies and 11 observational studies in 2019, the addition of HIPEC to cytoreductive surgery significantly improved overall survival of ovarian cancer patients. " 02/01/2014 - "Although the CRS and HIPEC procedure in the treatment of advanced or recurrent ovarian cancer represents now a reliable method with good results both in terms of morbidity and of distance results, there are still many controversial aspects that may in the future be better clarified only with a randomized phase III study, which is in progress, involving international working groups and experts on the procedure." 05/01/2012 - "HIPEC has been recently recommended as the 'new standard of care' for advanced ovarian cancer patients to treat residual disease, a recommendation based on the good results reported by many single institution studies. "
5.	Stomach Neoplasms (Stomach Cancer) 09/01/2020 - "The trial showed that in managing advanced gastric cancer patients (pT4a-4bN0-3 M0) by supplementing radical surgery with ACT-enhanced hyperthermic intraperitoneal chemotherapy, ACT proved to be highly effective when administered in its full mode of 7-8 cycles compared with its truncated variant of 1-6 cycles." 09/01/2022 - "Although p-HIPEC is effective in reducing the rate of peritoneal relapse and improving disease free and overall survival with or without adjuvant chemotherapy, when added to curative surgery in locally advanced, non-metastatic gastric cancers, the available literature is at best, heterogeneous, centre-specific and skewed. " 01/01/2016 - "In view of the acceptable morbidity and mortality rates we propose that CRS combined with HIPEC presents an effective and safe treatment modality for patients with gastric cancer, especially in cases where optimal cytoreduction is achieved before the HIPEC procedure." 08/01/2016 - "Therefore, HIPEC was found to improve survival in advanced gastric cancer patients with PM, but the difference was not statistically significant, which may be attributed to the small number of cases. " 12/01/2007 - "A significant improvement in survival was associated with hyperthermic intra-peritoneal chemotherapy (HIPEC) in patients with gastric cancer. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Oxaliplatin (Eloxatin)
3.	Mitomycin (Mitomycin-C)
4.	Platinum
5.	Paclitaxel (Taxol)
6.	lobaplatin
7.	Fluorouracil (Carac)
8.	Carboplatin (JM8)
9.	Aerosols
10.	Docetaxel (Taxotere)

Related Therapies and Procedures

1.	Hyperthermic Intraperitoneal Chemotherapy
2.	Cytoreduction Surgical Procedures
3.	Drug Therapy (Chemotherapy)
4.	Therapeutics
5.	Neoadjuvant Therapy